A USAID inspector general field operation in Kenya shut down at least four pharmacies, arrested two people, and seized thousands of stolen medical products, some expired, some diverted from American-funded global health programs.
The U.S. Agency for International Development's Office of Inspector General led the operation targeting Kenya's commercial pharmaceutical supply chain, where criminals had been funneling stolen medicine into back-channel pharmacies for resale. The OIG announced the results in a September 8 press release, detailing arrests, pharmacy shutdowns, and the recovery of a substantial cache of pilfered drugs and medical supplies.
Among the seized goods: more than 2,000 tablets of co-trimoxazole antibiotics, plus hundreds of expired, defective, or stolen tablets, capsules, and diagnostic test strips. Eleven additional individuals were compelled to report for further investigative or court proceedings. The OIG suspects some of the stolen products were diverted from U.S.-funded foreign assistance and global health programs, including programs operated under the United Nations, and some were apparently destined for shipment to other countries.
Former USAID Inspector General Jonathan Schofield described the operational approach in an interview on Just the News, No Noise last week. The agents doing this work are not desk-bound diplomats, he said.
"They're not sitting in the embassy. They're going out. They're doing field visits and interviews and conducting investigations that have had tremendous results."
The method is straightforward: OIG agents and local law enforcement tracked stolen or diverted products through the supply chain, arrested the sellers, interviewed them, and worked backward to identify their suppliers. The four pharmacies that were closed had been operating illegal schemes in violation of Kenyan regulations.
What makes the Kenya operation particularly alarming is the nature of the products involved. These are medicines and diagnostics funded by American taxpayers and intended for some of the world's most vulnerable patients. When those products vanish from legitimate distribution channels and resurface in unregulated pharmacies, the consequences extend well beyond financial loss.
Schofield drew on a prior, separate OIG operation across Africa, one targeting the theft of malaria and AIDS medication, to illustrate the human cost. In that earlier case, hundreds of millions of dollars' worth of medical commodities were being shipped annually from the United States to Africa. Criminals intercepted the supply.
"But these are criminals, so they weren't worried too much about refrigeration. They weren't worried about expiration dates. They wouldn't tell people how to administer whatever the product was."
The result, Schofield said plainly: "People were continuing, could get sick and die."
That earlier operation led to dozens of arrests across Africa and indictments in the United States. Afterward, the OIG worked with administrators on the continent to tighten controls and reduce product theft. The Kenya operation suggests the problem has not gone away, and that sustained enforcement, not one-time sweeps, is what keeps the pipeline from leaking.
Schofield framed the Kenya results as proof that the existing OIG workforce can protect foreign assistance dollars if it is empowered to do the job. He pointed to the investigators' track record and expertise as the critical asset.
"So, that is something that I think is a very, very important first step to remember in terms of how it is that foreign assistance can be protected moving forward. We have the answer. You have a really solid, experienced cadre of professionals who know how to address it."
The argument carries weight at a moment when Congress and the administration are scrutinizing how foreign aid money is spent and whether accountability mechanisms are keeping pace with the scale of U.S. commitments abroad. The Kenya operation offers a concrete example: boots on the ground, pharmacies shut down, suspects in custody, stolen medicine recovered before it could reach more patients under dangerous conditions.
Several questions remain unanswered. The OIG has not publicly identified the arrested individuals or the closed pharmacies by name. The specific U.S.-funded programs from which the products were diverted have not been disclosed. Nor has the agency said which other countries were slated to receive the stolen goods. The total dollar value of the seized products is also unknown.
Those gaps matter. Taxpayers funding these programs deserve a full accounting, not just of what was recovered, but of how the theft happened in the first place and who failed to stop it sooner.
When American-funded medicine meant for dying patients ends up expired on a black-market pharmacy shelf, the problem is not a lack of generosity, it is a lack of enforcement, and the people who pay for it are the patients who never got the drugs and the taxpayers who funded them.
